# A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

> **NCT01663272** · PHASE1 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** CABOZANTINIB
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT01663272
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-01
- **Final completion:** 2017-03-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01663272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01663272, "A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01663272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*